Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders
Proxygen, a leader in the discovery and development of molecular glue degraders, announced today that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. Proxygen is eligible to receive up to €495 million ($554 million at the average USD/EUR FX rate of Q1 2022) in continuous R&D funding, upfront and success-based pre-clinical, clinical, regulatory, and commercial milestones, as well as additional royalty payments. Under the terms of the agreement, the companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
“We are incredibly excited to start this long-term collaboration with Merck, a globally recognized player in the pharmaceutical industry that shares our drive towards dynamic innovation for the benefit of patients. The partnership validates the unique potential of Proxygen’s glue degrader platform and strategically leverages our common strengths in the targeted protein degradation field,” says Dr. Bernd Boidol, CEO of Proxygen.
Molecular glue degraders re-direct the cell’s own quality control machinery towards disease-causing proteins, inducing their selective and complete elimination. Because of their capability to modulate protein classes that would not be amenable to traditional drug discovery approaches, glue degraders hold the promise of unlocking a large proportion of the undruggable target space and delivering innovative therapies for diseases with high medical need. The lack of scalable discovery strategies has however so far hindered the full exploitation of the clinical potential of molecular glue degraders.
By streamlining and fully integrating cutting-edge genomic, proteomic, and biochemical technologies, Proxygen has successfully developed a highly versatile glue degrader discovery engine. The ligase-agnostic screening approach enables the specific and unbiased identification of molecular glue degraders against difficult-to-drug or completely undruggable targets at large scale. The vast amounts of know-how and data generated in the discovery and chemical optimization of degrader molecules continuously improve the understanding of this novel modality and contribute to Proxygen’s pioneering role in the molecular glue degrader space.
Founded in 2020, Proxygen is focused on the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. While advancing its internal programs towards clinical development, the company also maintains strategic partnerships to co-create synergies along the drug development pipeline. With its headquarters and laboratory operations in Vienna, Austria, Proxygen employs talent both locally and remotely all over Europe. For more information, please visit www.proxygen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Chief Executive Officer
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s TAKHZYRO ® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years1.7.2022 00:01:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.1 There are currently no long-term prophylactic (LTP) treatments approved for HAE patients younger than 6 years.2, 3, 4, 5 The primary objective of the open-label, multicenter, Phase 3 SPRING study was to evaluate the safety and pharmacokinetics (PK) of TAKHZYRO in patients aged 2 to <12 years with HAE. Clinical outcomes (prevention of HAE attacks) were measured as a secondary objective. “HAE is a rare condition where unpredictable symptoms like severely debilitating swelling can take a toll on children both physically and emotionally,” said Dr. Marcus Maurer, Professo
Venerable MMORPG Mabinogi Enters The Great Era Of Commerce With The First Of Two Summer Game Updates30.6.2022 22:20:00 CEST | Press release
Mabinogi, Nexon’s free-to-play fantasy MMORPG, announced gigantic two-part summer updates today, the first of which concentrates on the expansion of player Commerce, including upgrades to trading and bartering systems, new ports, plus entirely new merchant areas available in Iria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005876/en/ Nexon America's Mabinogi "Great Era of Commerce" (Graphic: Business Wire) In order to give Mabinogi’sworld of Erinn a more connected, energetic feel, ports have been reborn and a trade union was created featuring large ships to get players to their destinations faster. Build your merchant empire thanks to a brand new trade shop in Iria selling limited time items, and beneficial trade system changes that expand the Trading life skill with a host of economic additions. Rentable transportation, in the form of camels and dog sleds, are now available to be used for player trade runs. Player
Verisign Reports Internet Has 350.5 Million Domain Name Registrations at the End of the First Quarter of 202230.6.2022 22:06:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the first quarter of 2022 closed with 350.5 million domain name registrations across all top-level domains, an increase of 8.8 million domain name registrations, or 2.6%, compared to the fourth quarter of 2021.1,2 Domain name registrations have increased by 13.2 million, or 3.9%, year over year.1,2 The .com and .net TLDs had a combined total of 174.7 million domain name registrations in the domain name base3 at the end of the first quarter of 2022, an increase of 1.2 million domain name registrations, or 0.7%, compared to the fourth quarter of 2021. The .com and .net TLDs had a combined increase of 6.7 million domain name registrations, or 4.0%, year over year. As of March 31, 2022, the .com domain name base totaled 161.3 million domain name registrations, and the .net domain name base totaled 13.4 million domain name registrations. New .com and .net domai
Spinal Cord Stimulation Delivers Improved Arm Function30.6.2022 17:30:00 CEST | Press release
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces a Nature Neuroscience publication showing the potential for ONWARD’s ARCIM Therapy to restore movement and function in hands and arms after spinal cord injury. Regaining hand and arm function is the highest priority for many people with cervical spinal cord injury. Even mild functional deficits in hand and arm function lead to significantly reduced independence and quality of life. It has historically been challenging to develop new therapies for hand and arm function because their movements are complex and multidimensional. Researchers in today’s Nature Neuroscience publication investigated a potentially more effective approach to improving motor control of the upper limbs after spinal cord injury – an implantable neurostimulation system that modulates the spinal cord region involved in contr
NelsonHall Highlights the Strength of Mercans’ Global Employer of Record Services30.6.2022 16:00:00 CEST | Press release
“We are delighted that NelsonHall, the leading global analyst firm, has recognized Mercans as one of the fastest growing technology-driven global employer of record service providers. NelsonHall’s analyst report is a testament to the success of our EOR service line and demonstrates that our proprietary technology, combined with Mercans’ local presence in 160 countries, creates value for our customers and their employees,” said Tatjana Domovits, Group CEO of Mercans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005419/en/ Salman Saeed - Head of EOR - Mercans (Photo: AETOSWire) Mercans’ global employer of record services delivery model is unique in the industry and focuses on the excellence in customer and employee experience through digitalization, employee-centric support, and in-country expertise. Mercans has invested significantly in developing a proprietary global payroll software, HR Blizz™ with 160 country cover
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom